Stem cell transplantation for indolent lymphoma

Current Opinion in Hematology

Volumn 6, Issue 6, 1999, Pages 388-393

  Krackhardt, Angela ^a   Gribben, John G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOTRANSPLANTATION; ARTICLE; CANCER GRADING; CHRONIC LYMPHATIC LEUKEMIA; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HUMAN; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; RECURRENCE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0032692843     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199911000-00006     Document Type: Article

References (51)

1. 1 Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
2. 2 Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C, et al.: The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Blood 1998, 15:3562-3568.
3. 3 Horning SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993, 20:75-88.
4. 4 Coiffier B: Towards a cure in indolent lymphoproliferative diseases. Eur J Cancer 1995, 31:2135-2137.
5. 5 Hiddeman W: Non-Hodgkin's lymphomas-current status and future perspectives. Eur J Cancer 1996, 31A:2141-2145.
6. 6 Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, et al.: Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996, 347:353-357.
7. 7 Bastion Y, Brice P, Haioun C, Sonet A, Salles G, Marolleau JP, et al.: Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995, 86:3257-3262.
8. 8 Haas R, Moos M, Mohle R, Dohner H, Witt B, Goldschmidt H, et al.: High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Bone Marrow Transplantation 1996, 17:149-155.
9. + cell yield than patients in partial remission (P < 0.05). However, even after immunologic purging, all graft samples remained polymerase chain reaction (PCR)-positive.
10. 10 Dreger P, von Neuhoff N, Kuse R, Sonnen R, Glass B, Uharek L, et al.: Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure? Br J Cancer 1998, 77:2291-2297. This is a prospective single-center study of the use of stem cell transplantation in 18 patients with CLL, including early stage disease. Stem cell harvesting was successful in 14 patients, transplantation was performed in 13 patients. Of note, engraftment was delayed in patients receiving bone marrow in contrast to peripheral blood stem cells. Clonal PCR was detected in three patients post-transplant. However, polyclonal PCR resulted in all other transplanted patients with a median follow-up of 19 months and 12 patients are in complete clinical remission.
11. 11 Pavletic ZS, Bierman PJ, Vose JM, Bishop MR, Wu CD, Pierson JL, et al.: High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Ann Oncol 1998, 9:1023-1026. This is a small, single-center study of 13 patients with advanced CLL and 3 patients with small lymphocytic lymphoma investigating the long-term survival and relapse rates after autologous stem cell transplantation (SCT). High relapse rates raise the question of whether this therapy is superior to conventional therapy.
12. + cells, disease progression, or pretransplant therapy related deaths. Suggests that stem cell collection should be performed as soon as a first remission is obtained.
13. + cells of patients with B-cell chronic lymphocytic leukemia. Blood 1997, 89:4275-4281.
14. + stem cell mobilization in the peripheral blood. However, stem cell mobilization and collection could be performed following fludarabine treatment.
15. 15 Hassan HT, Hinz T, Kroger N, Zeller W, Zander AR: Factors influencing platelet recovery after autologous transplantation of G-CSF-mobilized peripheral blood stem/progenitor cells following myeloablative therapy in 50 heavily pretreated lymphoma patients. Clin Lab Haematol 1999, 21:21-27. This is a retrospective study of 50 heavily pretreated patients with Hodgkin's disease and non-Hodgkin's lymphoma, 23 of them with low-grade non-Hodgkin's lymphoma, who received autologous peripheral blood SCT. Factors influencing progenitor cell yield and platelet recovery were investigated, demonstrating regimens containing cytarabine and cisplatin to show significantly less progenitor yield and slower platelet recovery after transplantation.
16. 16 Morel P, Laporte JP, Noel MP, Lopez M, Douay L, Fouillard L, et al.: Autologous bone marrow transplantation as consolidation therapy may prolong remission in newly diagnosed high-risk follicular lymphoma: a pilot study of 34 cases. Leukemia 1995, 9:576-582.
17. 17 Freedman AS, Gribben JG, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, et al.: High dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996, 88:2780-2786.
18. 18 Fouillard L, Laporte JP, Labopin M, Lesage S, Isnard F, Douay L, et al.: Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation-results of a retrospective analysis on 120 patients autografted in a single institution. J Clin Oncol 1998, 16:2803-2816. These authors report retrospectively on the results of autologous peripheral blood stem cell transplantation in 120 patients with non-Hodgkin's lymphoma (aggressive and low-grade) treated at several disease stages. Patients who were transplanted in first remission had a significantly higher event-free survival than patients in first partial remission or second complete remission. Additional radiotherapy and graft purging with mafosfamide were associated with a higher event-free survival.
19. 19 Soiffer RJ, Freedman AS, Neuberg D, Fisher DC, Alyea EP, Gribben J, et al.: CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 1998, 21:1177-1181. This is a single-center study of 22 patients with different grades of non-Hodgkin's lymphoma undergoing allogeneic peripheral blood stem cell (PBSC) transplantation or bone marrow transplantation with CD6+ T cell depleted grafts. The authors suggest that CD6+ T cell depletion is associated with a lower risk of transplant-related complications.
20. 20 Juckett M, Rowlings P, Hessner M, Keever-Taylor C, Burns W, Camitta B, et al.: T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up. Bone Marrow Transplant 1998, 21:893-899. This is a retrospective review of 37 patients after T cell-depleted stem cell transplantation for aggressive (n=21) and indolent (n=16) non-Hodgkin's lymphoma. The authors suggest advantages of T cell depletion in patients with indolent lymphoma in contrast to patients with aggressive non-Hodgkin's lymphoma.
21. 21 Mach-Pascual S, Legare RD, Lu D, Kroon M, Neuberg D, Tantravahi R, et al.: Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: a single institution study. Blood 1998, 91:4496-4503. This is a single-institution study of predictive value clonality assays for the development of myelodysplastic syndrome or acute myeloid leukemia after autologous SCT for non-Hodgkin's lymphoma. Concludes that a significant proportion of patients have clonal hematopoiesis at the time of autologous SCT, which is predictitive for the development of t-myelodysplastic syndrome or acute myeloid leukemia.
22. 22 Stone RM: Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress? Blood 1994, 83:3437-3440.
23. 23 Gribben JG, Neuberg D, Freedman AS, Gimmi CD, Pesek KW, Barber M, et al.: Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993, 81:3449-3457.
24. 24 Zwicky CS, Maddocks AB, Andersen N, Gribben JG: Eradication of polymerase chain reaction immunoglobulin gene rearrangement in non-Hodgkin's lymphoma as associated with decreased relapse after autologous bone marrow transplantation. Blood 1996, 88:3314-3322.
25. 25 Corradini P, Astolfi M, Cherasco C, Ladetto M, Voena C, Caracciolo D, et al.: Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997, 89:724-731.
26. 26 Moos M, Schulz R, Martin S, Benner A, Haas R: The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma. Leukemia 1998, 12:1971-1976. This article confirms that the remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support is predictive for relapse-free survival in 47 patients with follicular lymphoma.
27. 27 Provan D, Bartlettpandite L, Zwicky C, Neuberg D, Maddocks A, Corradini P, et al.: Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996, 88:2228-2235.
28. 28 Magnac C, Sutton L, Cazin B, Laurent C, Binet JL, Merle-Beral H, et al.: Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL). Hematol Cell Ther 1999, 41:13-18. This small, single-center study confirms the potential of autologous SCT to achieve molecular remission in patients with CLL. Using a clone-specific PCR, minimal residual disease was detected in 11 of 12 patients after chemotherapy or autologous bone marrow transplantation. Molecular remission occurred in only one patient after autologous SCT.
29. 29 Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, et al.: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991, 325:1525-1533.
30. 30 Moos M, Schulz R, Cremer F, Sucker C, Schmohl D, Dohner H, et al.: Detection of minimal residual disease by polymerase chain reaction in B cell malignancies. Stem Cells 1995, 13 (Suppl 3):42-51.
31. 31 Andersen NS, Donovan JW, Borus JS, Poor CM, Neuberg D, Aster JC, et al.: Failure of immunologic purging in mantle cell lymphoma assessed by PCR detection of minimal residual disease. Blood 1997, 90:4212-4221.
32. 32 Jacquy C, Lambert F, Soree A, Van Daele S, Heusterspreute M, Bosly A, et al.: Peripheral blood stem cell contamination in mantle cell non-Hodgkin's lymphoma: the case for purging? Bone Marrow Transplant 1999, 23:681-686.
33. 33 Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al.: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
34. 34 Knox SJ, Goris ML, Trister K, Negrin R, Davis T, Liles TM, et al.: Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996, 2:457-470.
35. 35 Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H: Phase II multicenter study of human CD52 antibody in previously treated. J Clin Oncol 1997, 15:1567-1574.
36. 36 Verdonck LF, Dekker AW, Lockhorst HM, Peterson EJ, Nieuwenhuis HK: Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997, 90:4201-4205.
37. 37 Stein RS, Greer JP, Goodman S, Kallianpur A, Ahmed MS, Wolff SN: High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin. Bone Marrow Transplant 1999, 23:227-233. This article reports the results of high-dose chemotherapy followed by autologous or allogeneic transplantation in 51 patients from a single center. The authors suggest advantage of autologous transplantation because of the high mortality rate after allogeneic transplantation.
38. 38 Rabinowe SN, Soiffer RJ, Gribben JG, Daley H, Freedman AS, Daley J, et al.: Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993, 82:1366-1376.
39. 39 Khouri IF, Keating MJ, Vriesendorp HM, Reading CL, Przepiorka D, Huh YO, et al.: Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994, 12:748-758.
40. 40 Bernard M, Dauriac C, Drenou B, Leberre C, Branger B, Fauchet R, et al.: Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin's lymphoma. Bone Marrow Transplant 1999, 23:329-333. This is a small study of 13 patients with mainly advanced low-grade, intermediate-grade and aggressive lymphoma undergoing allogeneic SCT. Complete remission was achieved in 8 patients. The overall survival rate in this study was 67% and the median time of event-free survival was 102 months. Of note, donor lymphocyte infusion after relapse of two patients with low-grade lymphoma resulted in one partial and one complete remission which, however, was associated with grade IV acute graft-versus-host disease.
41. 41 van Besien KW, Mehra RC, Giralt SA, Kantarjian HM, Pugh WC, Khouri IF, et al.: Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med 1996, 100:299-307.
42. 42 van Besien KW, de Lima M, Giralt SA, Moore DF, Khouri IF, Rondon G, et al.: Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft versus lymphoma effect. Bone Marrow Transplant 1997, 19:977-982.
43. 43 van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO, Bishop MR, et al.: Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998, 92:1832-1836. This is a large multicenter study that confirms that high-dose therapy followed by allogeneic stem cell transplantation leads to prolonged survival in some patients with advanced low-grade lymphoma. It also confirms low relapse rate in allogeneic transplanted patients. However, the treatment-related mortality was 30 to 50%.
44. 44 Esteve J, Villamor N, Colomer D, Bosch F, Lopez-Guillermo A, Rovira M, et al.: Hematopoietic stem cell transplantation in chronic lymphocytic leukemia: a report of 12 patients from a single institution [see comments]. Ann Oncol 1998,9:167-172. This is a small, single-center study of 12 patients with CLL undergoing autologous or allogeneic stem cell transplantation. Long-lasting molecular complete remission could be observed in both settings.
45. 45 Khouri IF, Keating MJ, Champlin R: Hematopoietic stem cell transplantation for chronic lymphocytic leukemia. Curr Opin Hematol 1998, 5:454-459.
46. 46 Flinn IW, Vogelsang G: Bone marrow transplantation for chronic lymphocytic leukemia. Semin Oncol 1998, 25:60-64. This is a review of autologous and allogeneic stem cell transplantation in CLL.
47. 47 Waselenko JK, Flynn JM, Byrd JC: Stem-cell transplantation in chronic lymphocytic leukemia: the time for designing randomized studies has arrived. Semin Oncol 1999, 26:48-61. This is a review of the current status of stem-cell transplantation in CLL patients covering a large spectrum of aspects in autologous and allogeneic stem cell transplantation.
48. 48 Michallet M, Archimbaud E, Bandini G, Rowlings PA, Deeg HJ, Gahrton E, et al.: HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med 1996, 124:311-315.
49. 49 Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, et al.: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76:2462-2465.
50. 50 Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, et al.: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995, 86:1261-1268.
51. 51 Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S, et al.: Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998, 16:2817-2824. This single-center study demonstrates a direct graft-versus-lymphoma effect in 15 patients with CLL and low-grade or transformed low-grade non-Hodgkin's lymphoma. Patients received primarily a non-ablative immunosuppressive chemotherapy protocol followed by allogeneic stem cell infusion from HLA-identical siblings and in some cases donor lymphocyte infusion 2 to 3 months later. Eleven patients were engrafted successfully and 8 of 11 patients achieved a complete remission. Remission rate was significantly higher in patients with chemosensitive disease than in patients with refractory disease. However, acute or chronic graft-versus-host disease occurred in over 50% and was lethal in two patients. Whether there might be an advantage in event-free survival in contrast to non-transplanted patients remains to be shown.